Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool

Genome remodelling in a basal-like breast cancer metastasis and xenograft

(2010) Li Ding et al.   NATURE

PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer

(2009) R. J. Crowder et al.   CANCER RESEARCH

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

(2009) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene Expression Profiles Differentiating Between Breast Cancers Clinically Responsive or Resistant to Letrozole

(2009) William R. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

Routine Omission of Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma ≤ 1 cm Is Not Justified

(2009) Amod A. Sarnaik et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial

(2009) John A. Olson et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer

(2008) Jae Hong Seo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

(2008) M. J. Ellis et al.   JNCI-Journal of the National Cancer Institute